4DMedical Lands $15M Philips Commitment for North America Expansion

About 4D Medical Ltd

4DMedical Limited (ASX: 4DX) is a Melbourne-based medical technology company transforming respiratory diagnostics through advanced imaging and artificial intelligence. With headquarters in Australia and operations in the United States, the company specialises in analysing lung function from routine medical scans, delivering insights previously unavailable through conventional radiology. Its proprietary XV Technology and software platforms including XV LVAS, CT LVAS and CT:VQ provide clinicians with highly detailed ventilation and perfusion visualisation at the regional level, enabling earlier detection and improved monitoring of chronic lung disease.

In a major step forward for its commercial trajectory, 4DMedical has expanded its distribution agreement with Philips — one of the world’s largest medical imaging companies to include CT: VQ, the company’s FDA-cleared, non-contrast CT ventilation–perfusion imaging technology. The partnership marks a commercial inflection point for 4DMedical, significantly accelerating access to CT:VQ across the United States and Canada through Philips’ extensive sales infrastructure and hospital relationships.

A Major Commercial Expansion Into North America

Under the newly expanded agreement, Philips will add CT:VQ to its North American product portfolio on full commercial terms. Philips has also committed to a minimum of US$10 million in orders over CY26 and CY27, providing 4DMedical with revenue certainty as demand scales. The commitment is underwritten through agreed contractual milestones, ensuring predictable cash flow over the two-year period.

Philips will activate a dedicated team of sales and clinical specialists responsible for promoting CT:VQ across major health systems, imaging departments and community hospitals. This support will be amplified through joint marketing campaigns and co-branded initiatives, starting with the official commercial launch at RSNA 2025, the largest global radiology conference held annually in Chicago.

CT:VQ, A Technological Breakthrough in Lung Imaging

CT:VQ represents a major technological breakthrough in lung imaging as the first solution globally capable of producing quantitative ventilation–perfusion maps from a routine, non-contrast CT scan. By measuring subtle lung tissue motion and density changes, the technology allows clinicians to visualise airflow and blood-flow distribution with unprecedented precision. Unlike traditional nuclear VQ scans — which require radiotracers, complex regulatory oversight and specialist nuclear-medicine facilities — CT:VQ integrates seamlessly into existing CT workflows, needing no radiotracers, no contrast agents, no additional scanners and no specialised equipment. This delivers significant advantages, including streamlined scheduling, faster patient access, higher-resolution imaging, comprehensive quantitative reporting, and a far lower operational burden for hospitals. Because it is compatible with existing CT infrastructure, CT:VQ can be deployed rapidly across large health systems, including community and rural hospitals that lack nuclear imaging. With roughly 14,500 CT scanners already installed across the United States, the technology is uniquely positioned for national-scale rollout, substantially expanding access to advanced respiratory diagnostics.

A Multi-Billion Dollar Addressable Market

More than one million nuclear VQ scans are performed in the United States each year, with an average reimbursement per scan of approximately US$1,150. This represents an addressable US market of more than US$1.1 billion annually, and a US$2.6 billion global opportunity. Given CT:VQ’s operational simplicity, higher diagnostic precision and broad accessibility, 4DMedical expects the technology to displace 100% of all nuclear VQ scans over time. Management also anticipates that CT:VQ will expand the total market for ventilation–perfusion imaging by improving availability and enabling new diagnostic use cases. The Philips distribution agreement positions 4DMedical to capture a substantial portion of this market as adoption accelerates.

Strategic Significance and Market Position

The expanded Philips deal strengthens 4DMedical’s position as a global leader in functional lung imaging. By leveraging Philips’ deep relationships with hospitals, including large integrated delivery networks (IDNs), community health operators and academic medical centres, CT:VQ gains immediate access to a broad customer base. In addition to commercial scale, the partnership enhances clinical validation and brand credibility, critical factors in the highly regulated medical imaging sector. 4DMedical’s broader portfolio, bolstered by AI capabilities acquired through its 2023 acquisition of Imbio, enables the company to offer a comprehensive suite of lung analytics solutions delivered seamlessly through a SaaS model.

Outlook

4DMedical enters 2026 with significant commercial momentum. The Philips agreement provides both revenue visibility and accelerated distribution scale, supporting growth projections across the United States and Canada. The company anticipates further penetration into new clinical indications, expansion into additional health systems and steady growth in recurring SaaS revenue as CT:VQ adoption increases. With strong clinical evidence, scalable cloud-based delivery and a rapidly expanding partner ecosystem, 4DMedical is well positioned to become the global standard in ventilation–perfusion imaging.

Conclusion

4DMedical’s expanded distribution partnership with Philips marks a defining moment in the company’s commercial trajectory. With a guaranteed US$10 million order commitment, broad North American distribution and industry-leading imaging technology, the company is poised for rapid market penetration and sustained global growth.

As CT:VQ begins its full-scale commercial rollout, 4DMedical stands at the forefront of a major shift in respiratory diagnostics delivering faster, safer and more accessible lung imaging for clinicians and patients worldwide.